文献速递皮肤肿瘤

GJB5与皮肤恶性黑色素瘤BRAF突变及生存的关联

GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma.
PubMed 文献 · Br J Dermatol · 2021-10-10

该研究在黑色素瘤临床样本、细胞系及公共数据集中检测GJB5表达,发现转移灶和BRAF突变型黑色素瘤中GJB5表达显著下调,且GJB5低表达与患者总生存更差相关,尤其在早期阶段。机制上BRAFV600E通过上调miR-335-5p抑制GJB5,MAPK抑制剂治疗可上调GJB5。

要点

  • 转移性黑色素瘤中GJB5表达显著低于原发灶。
  • BRAF突变型黑色素瘤GJB5表达低于野生型,MAPKi治疗可上调GJB5。
  • GJB5低表达与患者总生存更差相关,尤其在早期阶段。

核心结论

  • 转移和BRAF突变与黑色素瘤中GJB5低表达显著相关。
  • GJB5低表达与患者总生存更差相关,尤其在早期阶段。
  • BRAFV600E通过上调miR-335-5p下调GJB5,MAPKi治疗可上调GJB5。

研究设计与样本

  • 在黑色素瘤临床样本和细胞系中检测GJB5的RNA和蛋白表达。
  • 细胞系包括经或未经BRAF和MEK抑制剂处理者及获得性MAPKi耐药者。
  • 用独立数据集(TCGA_SKCM)验证结果。

主要发现

  • 转移性黑色素瘤病灶GJB5表达较原发灶显著下调。
  • BRAF突变型黑色素瘤GJB5表达较BRAF野生型显著下调。
  • BRAFV600E细胞系GJB5表达显著低于BRAF野生型,MAPKi处理后升高。
  • MAPKi耐药细胞GJB5表达模式类似BRAF野生型,且与形态学改变相关。
  • TCGA_SKCM数据中BRAF突变与miR-335表达升高及GJB5表达负相关。

临床怎么用

  • GJB5低表达可能作为皮肤黑色素瘤预后标志物,尤其用于早期患者风险分层。
  • BRAF突变状态与GJB5表达相关,MAPKi治疗可上调GJB5,提示潜在治疗相关机制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Gap-junctional intercellular communication is crucial for epidermal cellular homeostasis. Inability to establish melanocyte-keratinocyte contact and loss of the intercellular junction's integrity may contribute to melanoma development. Connexins, laminins and desmocollins have been implicated in the control of melanoma growth, where their reduced expression has been reported in metastatic lesions. OBJECTIVES: The aim of this study was to investigate connexin 31·1 (GJB5) expression and identify any association with BRAF mutational status, prognosis of patients with melanoma and mitogen-activated protein kinase (MAPK) inhibitor (MAPKi) treatment. METHODS: GJB5 expression was measured at RNA and protein level in melanoma clinical samples and established cell lines treated (or not) with BRAF and MEK inhibitors (MEKi), as well as in cell lines which developed MAPKi resistance. Findings were further validated and confirmed by analysis of independent datasets. RESULTS: Our analysis reveals significant downregulation of GJB5 expression in metastatic melanoma lesions compared with primary ones and in BRAF-mutated vs. BRAF-wildtype (BRAFWT ) melanomas. Likewise, GJB5 expression is significantly lower in BRAFV600E compared with BRAFWT cell lines and increases on MAPKi treatment. MAPKi-resistant melanoma cells display a similar expression pattern compared with BRAFWT cells, with increased GJB5 expression associated with morphological changes. Enhancement of BRAFV600E expression in BRAFWT melanoma cells significantly upregulates miR-335-5p expression with consequent downregulation of GJB5, one of its targets. Furthermore, overexpression of miR-335-5p in two BRAFWT cell lines confirms specific GJB5 protein downregulation. Reverse transcriptase quantitative polymerase chain reaction analysis also revealed upregulation of miR-335 in BRAFV600E melanoma cells, which is significantly downregulated in cells resistant to MEKi. Our data were further validated using the TCGA_SKCM dataset, where BRAF mutations associate with increased miR-335 expression and inversely correlate with GJB5 expression. In clinical samples, GJB5 underexpression is also associated with patient overall worse survival, especially at early stages. CONCLUSIONS: We identified a significant association between metastases/BRAF mutation and low GJB5 expression in melanoma. Our results identify a novel mechanism of gap-junctional protein regulation, suggesting a prognostic role for GJB5 in cutaneous melanoma.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Scatolini M, Patel A, Grosso E, et al. GJB5 association with BRAF mutation and survival in cutaneous malignant melanoma. Br J Dermatol. 2021. PMID: 34240406. doi:10.1111/bjd.20629

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。